Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Petershill Partners reports solid profit growth, upbeat outlook

(Sharecast News) - Petershill Partners has unveiled another special dividend payment after a solid increase in profits in 2024, as the private equity group painted a confident outlook for future shareholder returns. The company, which was established by Goldman Sachs back in 2007, said it would return a further $151m to shareholders through a 14 cents-per-share special dividend, reflecting the gains made on the sale of its stake in venture capital firm General Catalyst announced in January.

The payment follows two special dividend payments worth a total of $287m in respect of 2024, which when combined with an interim and final dividend, tender offer and buyback, took the total capital return for the financial year to $563m.

Adjusted pre-tax profit rose to $216m in 2024, up from $200m in 2023, with total income up to $332.3m from $319.4m, helped by double-digit growth in parter fee-related earnings.

Aggregate partner-firm assets under management rose 11% over the year to $337bn.

"In 2024 there was positive momentum across the business, and we delivered successfully on our financial and strategic goals," said Ali Raissi-Dehkordy and Robert Hamilton Kelly, co-heads of Goldman Sachs Petershill Group.

"We are pleased with our Partner-firms asset raising meeting or exceeding our guidance for three consecutive years, against three years of lower industry asset raising."

Looking ahead, the company said that, despite the uncertain geopolitical and economic environment, "our robust capital raising and dynamic approach to capital allocation underpins our confidence in our strategy and generating strong returns for shareholders".

Shares were down around 3.4% at 233.85p by 1110 GMT, having jumped by around a quarter over the past 12 months..

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.